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Abstract
There is overwhelming clinical evidence that the extracellular-regulated protein kinase 5 (ERK5) is significantly
dysregulated in human breast cancer. However, there is no definite understanding of the requirement of ERK5 in tumor
growth and metastasis due to very limited characterization of the pathway in disease models. In this study, we report that a
high level of ERK5 is a predictive marker of metastatic breast cancer. Mechanistically, our in vitro data revealed that ERK5
was critical for maintaining the invasive capability of triple-negative breast cancer (TNBC) cells through focal adhesion
protein kinase (FAK) activation. Specifically, we found that phosphorylation of FAK at Tyr397 was controlled by a kinase-
independent function of ERK5. Accordingly, silencing ERK5 in mammary tumor grafts impaired FAK phosphorylation at
Tyr397 and suppressed TNBC cell metastasis to the lung without preventing tumor growth. Collectively, these results
establish a functional relationship between ERK5 and FAK signaling in promoting malignancy. Thus, targeting the
oncogenic ERK5-FAK axis represents a promising therapeutic strategy for breast cancer exhibiting aggressive clinical
behavior.
Introduction
The overall survival of breast cancer patients has increased
quite remarkably over the past few decades as a con-
sequence of the introduction of early detection programs,
but also due to the utilization of improved treatment pro-
tocols based on molecular and genomic diagnostics [1]. In
particular, patterns of expression of the estrogen receptor
(ER), progesterone receptor (PR) and human epidermal
growth factor receptor 2 (HER2) constitute effective pre-
dictive markers for potential responses to endocrine treat-
ment, the humanized monoclonal anti-HER2 antibody
trastuzumab (Herceptin®) and the small protein tyrosine
kinase inhibitor lapatinib [2, 3]. In spite of these marked
therapeutic advances, the most aggressive basal-like tumors,
which largely overlap with the triple ER, PR and HER2
negative subtype of breast cancer (TNBC), continue to
present a significant clinical challenge due to the limited
availability of treatment options [2, 3]. Notably, regardless
of the combination chemotherapy regimen given, many
responses in the metastatic setting are short, with a median
overall survival being of less than 2 years [3]. Therefore, the
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identification of relevant biomarkers has become of para-
mount importance for guiding the future development of
efficacious targeted therapies to improve TNBC patient
outcome.
Signal transduction via mitogen-activated protein kinases
(MAPK) are frequently dysregulated in many types of
cancer. In particular, there is clinical evidence that over-
expression and hyperphosphorylation of the extracellular-
regulated protein kinase 5 (ERK5) are associated with
overall poor survival rates of breast cancer patients and
resistance to chemotherapy [4–7]. Accordingly, mammary
graft studies, using human (MDA-MB-231) or murine
(4T1) breast cancer cell lines that mirror the molecular
subtype of TNBC, demonstrated that ERK5 knockdown
suppressed metastasis [8–10]. Interestingly, mice trans-
planted with MDA-MB-231 cells in which ERK5 was
silenced exhibited a decreased number of circulating tumor
cells in the blood compared with those transplanted with
wild type MDA-MB-231 cells [9]. Collectively these
observations in murine models added weight to the argu-
ment, from the analysis of patient tumor samples, that
ERK5 targeting represented a valid strategy against meta-
static breast cancer.
In contrast, there is no clarity in understanding the
mechanism by which ERK5 influences metastasis-related
tumor cell function. For example, ERK5 could function via
rearranging the epithelial phenotype of breast cancer cells
to acquire migratory and invasive characteristics [9–11].
This has been disputed by other studies which suggested
that ERK5 attenuated breast cancer cell motility and sup-
pressed mammary tumor metastasis through negative reg-
ulation of mesenchymal markers [12, 13]. Additionally,
ERK5 was found to be a target of the focal adhesion pro-
tein kinase (FAK) in breast cancer cell adhesion signaling
[14]. However, a functional relationship between ERK5
and FAK signaling in the pathogenesis of metastatic breast
cancer has never been fully investigated in vivo. Further-
more, the precise mechanistic interaction between ERK5
and FAK remains unclear. In particular, while ERK5 was
initially found to be a target of FAK [14], other studies
demonstrated that ERK5 promoted breast cancer cell pro-
liferation [15], adhesion-dependent survival [16], and
melanoma cell invasiveness [17] through FAK phosphor-
ylation at Ser910.
In this study, we have utilized the triple-negative MDA-
MB-231 breast cancer line and selective short hairpin RNA
(shRNA) knockdown strategy to assess the cellular function
under the control of ERK5 that influences the course of
breast tumor progression and metastasis. The demonstration
that ERK5 was required for FAK phosphorylation at
Tyr397 and breast cancer metastasis identifies a previously
untargeted signaling axis implicated in tumor cell migration
for distant metastasis formation.
Results
High ERK5 expression serves as a potentially
important prognostic indicator of breast cancer
malignancy and poor prognosis
Initially, we investigated the clinical significance of ERK5
in breast cancer using the Kaplan–Meier Plotter database
tool (kmplot.com). We found that the level of ERK5
expression inversely correlated with distant metastasis-free
survival across all subtypes (hazard ratio= 1.3, p value=
0.01; Fig. 1). The association of ERK5 expression with the
metastatic spread of the disease was statistically significant
in later stage breast cancer (all hazard ratios ≥1.5, p value=
0.3 for grade 1 compared with <0.02 for grades 2 and 3). In
parallel, the analysis of a large transcriptomic dataset of
breast tumors from The Cancer Genome Atlas (TCGA) [18]
indicated that basal-like tumors exhibited the highest
expression level of Erk5 transcript among all subtypes, i.e.,
luminal and HER2-positive subgroups (Fig. 2A). Triple-
negative molecular subtyping is routinely utilized in the
clinic as a surrogate classification for aggressive basal-like
tumors lacking ER/PR and HER2 expression. We found a
robust inverse correlation between the level of ERK5
expression and metastasis-free survival of TNBC patients
(hazard ratio= 6.9, p value= 0.03; Fig. 2B).
We subsequently analyzed by immunohistochemistry
biopsies of human triple-negative ductal carcinoma and
adjacent normal breast tissue, as well as lung metastatic
sites. In normal breast and lung tissues, ERK5 was speci-
fically detected in acini, ducts and alveoli (Fig. 2C and
Supplementary Fig. S1). Higher magnifications clearly
demonstrated a predominant ERK5 staining in the cyto-
plasm of mammary acinar cells. Unlike normal tissue, high-
grade invasive ductal carcinoma appeared highly dis-
organized. The notable absence of tubule formation was
associated with the presence of numerous pleomorphic cells
exhibiting increased mitotic activity (Fig. 2C and Supple-
mentary Fig. S1). Nonetheless, ERK5 remained pre-
dominantly cytoplasmic in cancerous cells with some
evidence of perinuclear staining, suggesting that ERK5 was
not constitutively activated in triple-negative ductal carci-
noma (Fig. 2C and Supplementary Fig. S1). A similar
pattern of ERK5 staining was detected in metastatic breast
cancer cells from lung biopsies (Supplementary Fig. S1).
Moreover, we confirmed that the protein abundance of
ERK5 was higher in TNBC cell lines (MDA-MB-231 and
MDA-MB-468) compared with HER2-positive breast can-
cer cells (BT474, SK-BR-3 and MDA-MB-453) (Supple-
mentary Fig. S2A). Remarkably, ERK5 expressed in TNBC
cells did not exhibit the typical mobility shift by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) char-
acteristic of ERK5 activation by hyperphosphorylation
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downstream of HER2 stimulation [19]. The absence of
ERK5 hyperphosphorylation in TNBC cell lines was con-
sistent with the lack of nuclear ERK5 staining in sections of
human triple-negative breast carcinoma.
ERK5 is required for breast cancer cell invasion and
the suppression of E-cadherin expression
To gain further insights into the oncogenic function of
ERK5 in breast cancer, we engineered stable ERK5
knockdown in MDA-MB-231 cells using two distinct
shRNAs targeting the 3′UTR or the coding sequence (CDS)
of ERK5. MDA-MB-231 cells transduced with non-target
scrambled (Scr) shRNA were utilized as controls. The
efficacy of both shRNA to silence ERK5 expression was
demonstrated by immunoblot analysis (Fig. 3A, B).
In contrast to ERK5 inhibition by XMD8–92 [20], ERK5
knockdown did not prevent the growth of MDA-MB-231
cells (Supplementary Fig. S2B). Instead, we found that
ERK5 silencing significantly impaired breast cancer cell
invasion through the Matrigel under fetal bovine serum
(FBS)-free condition or in response to EGF treatment, but
not following FBS stimulation (Fig. 3C and Supplementary
Fig. S2C). Importantly. we confirmed that the invasive
capability of shERK5(UTR)-expressing MDA-MB-231
cells was restored following doxycycline-induced expres-
sion of FLAG-tagged (F) ERK5 wild type (WT) at a level
similar to that of the endogenous protein (Fig. 3B, C).
Additionally, real-time quantitative IncuCyte® live cell
imaging revealed that silencing ERK5 reduced by around
two-fold the kinetic of breast cancer cell adhesion to
Matrigel-coated plates, independently of increased cell
death up until 12 h after seeding (Fig. 3D and Video 1).
Adherent shERK5(UTR)-expressing MDA-MB-231 cells
detected at the end of the experiment exhibited a mor-
phology similar to that of control shScr cell line (Video 1).
Fig. 1 ERK5 expression
strongly associates with
metastatic occurrence in
breast cancer. The relationship
between the level of ERK5
expression and distant
metastasis-free survival of breast
cancer (BC) patients was
assessed by Kaplan–Meier
plotter. Independent cohorts of
patients with early (grade 1) or
late (grades 2 and 3) stage
disease status were analyzed.
Samples were divided into two
groups with high (red) and low
(black) expression of ERK5.
Hazard ratios (HR) and logrank
P values are shown.
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The reduced invasive capability of MDA-MB-231 cells
caused by ERK5 silencing correlated with increased
expression of the epithelial marker E-cadherin (Fig. 3E).
Although the level of the E-cadherin transcript was not
significantly altered, this coincided with a marked reduction
in the expression of Slug, a transcriptional repressor of E-
cadherin involved in EMT (Fig. 3E, F). Conversely, protein
and RNA levels of Snail, another important transcriptional
repressor of E-cadherin, were increased in shERK5(UTR)-
compared with shScr-expressing MDA-MB-231 cells, while
the transcript level of other mesenchymal markers (e.g.,
N-cadherin, MMP2, Vimentin) was unchanged (Fig. 3F).
Fig. 2 ERK5 is overexpressed
in TNBC and its
overexpression strongly
correlates with poor
prognosis. A The level of Erk5
transcript was analyzed in 416
luminal/HER2+ tumors and 98
TNBC from TCGA dataset.





of TNBC patients. Samples were
divided into two groups with
high (red) and low (black)
expression of ERK5. Hazard
ratio (HR) and logrank P values
are shown. C A biopsy of
human invasive ductal
carcinoma and adjacent normal
breast tissue (patient #481) was
stained with H&E or with a
specific antibody to ERK5
(brown). Scale bars: (2.5x)
500 μm, (10x) 100 μm, (40x)
20 μm.
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FAK is a potentially important regulator of breast
cancer metastasis controlled by a kinase-
independent function of ERK5
To further explore the underlying mechanism of ERK5-
mediated breast cancer cell invasion, we tested the asso-
ciation between ERK5 and FAK, a non-receptor protein
tyrosine kinase that plays a prominent role in cell spreading
and migration, and the initiation of various malignancies
[21]. The best-characterized mechanism that promotes FAK
activation upon cell interactions with the extracellular
matrix involves FAK dimerization and subsequent autop-
hosphorylation at Tyr397 [22]. Interestingly, ERK5-
mediated FAK phosphorylation at Ser910 during mela-
noma cell migration coincided with decreased phosphor-
ylation at Tyr397 [17].
Here, we found that a proportion of ectopically expressed
F-ERK5(WT) in shERK5(UTR)-expressing MDA-MB-231
cells co-localized with phosphorylated FAK at Tyr397 in
focal adhesion sites (Fig. 4). Three-dimensional confocal
microscopy clearly showed dual staining of F-ERK5(WT)
and phospho (p)-FAK(Y397) at cell surface attachment
Fig. 3 ERK5 silencing
suppresses breast cancer cell
invasion. A, B Immunoblot
analysis confirmed that shERK5
(UTR) and shERK5(CDS)
effectively downregulated
ERK5 expression in MDA-MB-
231 cells. Ectopic expression of
ERK5 [+ F-ERK5(WT)] at a
level similar to that of the
endogenous protein was
achieved by incubating shERK5
(UTR)-expressing cells carrying
an inducible F-ERK5(WT)
construct with 10 ng/ml
doxycycline (+) for 24 h. C
ERK5 knockdown suppressed
MDA-MB-231 cell invasion in
FBS-free medium through
Matrigel. The bar graph
indicates the mean ± SD (N= 3).
Representative pictures of the
filters are shown. Scale bar:
200 μm. D Quantitative time
course analysis of MDA-MB-
231 cell adhesion on Matrigel by
IncuCyte® live-cell imaging
system. Representative pictures
of cells taken 4 h after seeding in
Matrigel-coated plates are
shown. The data correspond to
the mean ± SD (N= 3). E
Lysates were obtained from cells
cultured in FBS-free Matrigel-
coated plates for 12 h and
analyzed by immunoblot. The
images are representative of
three biological repeats. F
Alternatively, transcript levels
were measured by quantitative
real-time PCR. Results are
presented as fold change ± SD.
The graph is representative of
three independent biological
repeats performed in duplicate.
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points with the Matrigel (Video 2). We subsequently con-
firmed by in situ proximity ligation assay (PLA) that
F-ERK5(WT) could be detected in very close proximity
with FAK, indicative of the existence of an ERK5-FAK
complex (Fig. 5A). The specificity of this interaction was
supported by evidence that a C-terminal truncated ERK5
mutant [F-ERK5-ΔC(1–575)] displaying a predominant
nuclear localization [23] did not associate with FAK
(Supplementary Fig. S3A).
In parallel, we discovered that ERK5 silencing in breast
cancer cells inhibited FAK phosphorylation at Tyr397 (Fig.
5B). The demonstration that doxycycline-induced expres-
sion of F-ERK5(WT) restored normal level of FAK phos-
phorylation in shERK5(UTR)-expressing MDA-MB-231
Fig. 4 ERK5 co-localizes with
p-FAK in focal adhesions.
iRFP720+ MDA-MB-231 cells
carrying shERK5(UTR) were
incubated for 24 h with 2 μg/ml
doxycycline to induce F-ERK5
(WT) expression, prior to being
seeded on glass bottom dish
coated with Matrigel and






antibodies to the FLAG epitope
(M2, green) and to p-FAK
(Y397) (red). Nuclei were
detected with DAPI (blue).
Images at different Z positions
are shown. Scale bars: 10 μm.
The inset shows a higher
magnification of focal adhesions
where F-ERK5 and p-FAK
(Y397) co-localized. Violet
arrows highlight yellow staining
indicative of F-ERK5/p-FAK
(Y397) co-localization.
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cells confirmed that ERK5 was required for FAK activation
in response to signals from the extracellular matrix (Fig.
5C). Remarkably, normal FAK phosphorylation in shERK5
(UTR)-expressing MDA-MB-231 cells was also achieved
following induced expression of F-ERK5(D200A), a kinase
dead mutant of ERK5 unable to bind ATP [24] (Fig. 5C).
We confirmed that JWG-045, a novel pharmacological
inhibitor of ERK5 exhibiting significantly reduced affinity
for BRD4 compared with XMD8–92 [25, 26], did not
suppress FAK phosphorylation at Tyr397 in MDA-MB-231
cells (Supplementary Fig. S3B, C). Interestingly, neither
ERK5 silencing nor incubation with JWG-045 affected the
level of FAK phosphorylation at Ser910 (Supplementary
Fig. S3C). Collectively, these results demonstrated that
ERK5 controlled the post-translational modification of FAK
at Tyr397, independently of its catalytic activity. Accord-
ingly, F-ERK5(D200A) was able to associate with FAK
(Fig. 5D) and also to rescue the invasion defect caused by
ERK5 silencing (Supplementary Fig. S3D, E).
The functional importance of FAK activation down-
stream of ERK5 was demonstrated by evidence that over-
expression of tyrosine phosphorylated FAK at the cell
membrane [myristoylated (myr)FAK; [27] rescued the
invasion defect caused by ERK5 silencing (Supplementary
Fig. S3D, E). Additionally, we confirmed the clinical sig-
nificance of FAK in TNBC (Supplementary Fig. S4A–C).
Consistent with evidence that FAK signaling inversely
correlated with metastasis-free survival, inhibiting FAK
activity by incubating MDA-MB-231 cells with PND1186
[28] significantly decreased their ability to invade through
the Matrigel (Supplementary Fig. S4D). However,
PND1186 did not affect the level of ERK5 expression and
ERK1/2 phosphorylation (Supplementary Fig. S4E). Like-
wise, FAK inhibition did not affect the expression of E-




for 24 h with 2 μg/ml
doxycycline to induce F-ERK5
(WT) (A) or F-ERK5(D200A)
(D) expression. Cells were
subsequently seeded on
Matrigel-coated glass bottom
plate for 6 h prior to being fixed
and incubated with antibodies to
the FLAG epitope (M2) and
p-FAK(Y397). Negative
controls included incubation
with each primary antibody
separately and no primary




according to the Duolink® PLA
fluorescence protocol (Sigma).
Images were acquired by
fluorescence microscopy. Scale
bars: 10 μm. B, C Lysates were
obtained from cells cultured in
FBS-free Matrigel-coated plates
for the indicated times. In panel
C, iRFP720+ cells expressing
shERK5(UTR) were incubated
with 10 ng/ml doxycycline for
24 h to induce F-ERK5(WT) or
F-ERK5(D200A) expression,
prior to being seeded. MDA-
MB-231 cells expressing shScr
control or transduced with an
empty pCHD plasmid (−) were
utilized as controls. Similar
results were obtained in two
independent experiments.
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cadherin, indicating that FAK was not involved in main-
taining the mesenchymal phenotype of MDA-MB-231 cells
downstream of ERK5 (Supplementary Fig. S4E).
ERK5 is a critical component of malignant
progression of breast cancer through FAK
phosphorylation
To confirm the requirement of the ERK5-FAK axis in
promoting breast cancer metastasis, we performed tumor-
igenesis assays in nude mice. First, we created a novel
stable MDA-MB-231 cell line to permit doxycycline-
inducible ERK5 knockdown in vivo (Supplementary Fig.
S5A). MDA-MB-231 cells carrying the shERK5i-
Luc2=tdT construct were transplanted into the mammary
fat pad of athymic female CD1 mice to allow orthotopic
tumor formation. Animals exhibiting small tumors (between
10 and 80 mm3 at day 20) were subsequently fed with a
doxycycline containing diet (dox+) to silence ERK5 in
breast cancer cells, or with a standard doxycycline-free
(dox−) control diet. The presence of doxycycline in the
serum of dox+ mice was confirmed by using mass-
spectrometry analysis of terminal cardiac blood puncture
samples (Supplementary Fig. S5B).
Initially, ERK5 silencing appeared to cause a slight
decrease in tumor growth (Fig. 6A). However, no sig-
nificant difference in tumor size was measured until the
absence of ERK5 begun to noticeably accelerate the growth
of orthotopic mammary grafts in mice exposed to doxycy-
cline for 3.5 weeks, corresponding to 44 days post trans-
plantation (Fig. 6B). A similar impact of ERK5 silencing on
tumor growth was observed in a preliminary small pilot
experiment in which MDA-MB-231 cells carrying the
shERK5i-Luc2=tdT construct were transplanted sub-
cutaneously into the back of adult female CBA nude mice
(Supplementary Fig. S6A, B). Immunostaining of harvested
tumor sections confirmed efficient silencing of ERK5 in
orthotopic mammary grafts excised from dox+ CD1 mice
(Fig. 6C). Remarkably, the reduction in ERK5 expression
correlated with decreased p-FAK(Tyr397) staining, con-
sistent with the requirement of ERK5 for mediating FAK
activation in vivo (Fig. 6C). Accordingly, human invasive
ductal carcinoma biopsies exhibiting high ERK5 expression
displayed high level of p-FAK(Tyr397) (Supplementary
Fig. S7).
Mice cohorts were subsequently organized in pairs of
dox+ and dox− animals according to similar size of tumor
volumes (Fig. 7A). The presence of tdT+ metastatic breast
cancer cells in the lungs of mice carrying orthotopic
mammary tumor grafts was quantified post-mortem by flow
cytometry (Fig. 7A, B). Consistent with the requirement of
ERK5 for mediating breast cancer cell invasion in vitro, the
absence of ERK5 notably suppressed breast cancer lung
metastasis in vivo. The remaining low incidence of lung
metastasis detected in the dox+ group was likely a con-
sequence of residual ERK5 level in shERK5i-expressing
MDA-MB-231 cells that would be expected in any silen-
cing approach by means of inducible shRNA. Breast cancer
cell metastasis to the spleen and the bone was also captured
by bioluminescence imaging in one control animal among
all recipient mice analyzed (Fig. 7C).
Discussion
We have demonstrated for the first time that induced
ERK5 silencing in small TNBC grafts accelerated the
dynamic of tumor growth, suggesting that ERK5 could
antagonize mitogenic signaling to maintain cancer cell
survival in established tumors. This hypothesis contradicts
previous reports that demonstrated that ERK5 knockdown
did not affect the growth of primary triple-negative mam-
mary tumors [8–10, 13]. Moreover, a recent publication
provided new genetic evidence supporting the requirement
of ERK5 in promoting tumorigenesis [29]. These conflict-
ing findings highlight that continued efforts need to be made
to resolve the ongoing controversy about the involvement of
ERK5 in tumor growth during the early stage development
of breast cancer. Nevertheless, ERK5 remains a clinically
relevant therapeutic target in TNBC given its strong asso-
ciation with increased metastatic risk (8–10, 29, this study).
Disruption of the actin cytoskeleton by Src through
ERK5-dependent transcription constituted the first evidence
that ERK5 signaling altered the invasiveness of transformed
cells [30, 31]. Here, we proposed that ERK5 maintained the
invasive capability of breast cancer cells through FAK-
mediated regulation of cell adhesion. Accordingly, we
provided the first demonstration that decreased malignancy
caused by ERK5 ablation associated with the loss of FAK
phosphorylation at Tyr397 in mammary tumor grafts. Given
the functional interaction between of Src and FAK in focal
adhesion remodeling [32], this new finding emphasized a
potentially important a role of ERK5 in metastatic mam-
mary tumors with elevated c-Src kinase activity. An alter-
native mechanism underlying the metastatic effect of ERK5
involved the breast tumor kinase (Brk) downstream of the
MET receptor [33, 34]. This might also be significant given
that Brk is overexpressed in a majority of breast tumors,
whilst undetectable in normal mammary gland [35].
Remarkably, ERK5-mediated FAK phosphorylation at
Tyr397 in TNBC cells did not require ERK5 activity,
suggesting that ERK5 could act as a scaffold protein to
support cell invasion through FAK. Interestingly, ERK5
was mostly detected in the cytoplasmic compartment of
cancerous cells in TNBC patients, consistent with the idea
that ERK5 overexpression rather than hyperactivation is a
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significant feature of high-grade triple-negative invasive
ductal carcinoma in humans. Conversely, ERK5 silencing
did not affect FAK phosphorylation at Ser910, a site
previously found to be phosphorylated by ERK1/2 [36],
but also by ERK5 [17–19]. Increased FAK phosphoryla-
tion at Ser910 in response to ERK5 activation by MEK5
constituted an important mechanism for mediating
melanoma lung metastasis [19]. Interestingly, high level of
ERK5 and phosphorylated FAK at Ser910 in highly
metastatic murine melanoma and human lung cancer cell
lines coincided with low FAK phosphorylation at Tyr397
[19]. A dual function of ERK5 as a scaffold protein (our
results) and an enzyme [17–19] might explain these
apparent conflicting results.
Fig. 6 Induced ERK5 silencing




cells carrying shERK5i were
orthotopically transplanted into
the mammary fad pad of CD1
nude mice. A Representative
bioluminescence images of
mammary tumors just before
(day 20) and after mice were fed
with doxycycline for 12 and
22 days. B Tumors were
measured on average twice a
week for the duration of the
experiment. The data presented
as fold increase in the volume of
tumor size after the introduction
of the dox diet at day 20
correspond to the mean ± SD.
After 4 weeks, animals in the
dox− and dox+ cohorts
exhibiting large tumors or a
change in normal behavior were
humanely culled. Total N
number of animals analyzed per
condition over the duration of
the experiment is indicated. C
Tumors were collected 4 weeks
after exposure to doxycycline
and analyzed by
immunohistochemistry with a
specific antibody to ERK5 or to
p-FAK(Y397). Scale bars: (40x)
20 μm.
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In line with this idea, the estrogen receptor (ER)α was
found to suppress breast cancer cell motility and invasion
by recruiting ERK5 to the nucleus, thereby restricting the
formation of an ERK5/cofilin complex in actin-rich regions
of the cytoplasmic membrane [37]. Although the paper did
not rigorously address whether or not ERK5 promoted the
aggressiveness of ERα(−) breast cancer cells through
modulating actin dynamics independently of its catalytic
activity, estrogen-mediated transcription in ERα(+) breast
cancer cells required ERK5 activation by MEK5 [38].
Interestingly, ectopic expression of MEK5 had been pre-
viously shown to promote a more malignant phenotype by
repressing ERα expression and by promoting epithelial
mesenchymal transition (EMT), a well-known reprogram-
ing process that confers metastatic properties to cancer cells
[38–40].
Through genetic ablation and silencing approaches,
ERK5 was also shown to be essential for maintaining
mesenchymal features of MDA-MB-231 tumor grafts
[9, 10, 29]. We confirmed that ERK5 suppressed the level
of the epithelial marker E-cadherin downstream of Slug.
This was not observed in PND1186-treated cells, suggesting
that the impact of ERK5 silencing on E-cadherin expression
was independent of impaired FAK signaling. Consistent
with the CRISPR/Cas9 knock-out approach [29],
ERK5 silencing increased the level of Snail. In contrast, we
found no evidence that ERK5 altered the level of various
mesenchymal markers, e.g., N-cadherin, vimentin, or
expression of MMP2, a member of the MMP family known
to potentiate cancer cell dissemination through degrading
ECM. Moreover, the downregulation of ERK5 did not
prevent adherent MDA-MB-231 cells from acquiring the
typical stellate morphology characteristic of highly aggres-
sive mesenchymal breast cancer model. These results led us
to conclude that, although ERK5 might contribute to con-
trolling the expression level of certain epithelial and
mesenchymal markers, the pathological context under
which inhibition of the ERK5 pathway is sufficient to
reprogram an epithelial phenotype from an aggressive
mesenchymal breast cancer model remains unknown.
In summary, we presented strong evidence that ERK5
overexpression was an important feature of TNBC metas-
tasis through the regulation of cell adhesion via FAK.
Based on our findings, we hypothesize that ERK5 might
contribute to the dimerization of FAK as a prerequisite to
FAK activation at focal adhesion sites, via its unique
domain structure [23]. In particular, the C-terminal tail of
ERK5 that comprises multiple phosphorylation sites, as
well as proline-rich sequences, provides ideal binding
motifs to serve a scaffolding function of ERK5 in TNBC
[24, 41]. Thus, it will be critical to identify the membrane-
associated ERK5 protein complex for understanding the
requirement of ERK5 in FAK-mediated metastasis through
controlling focal adhesion dynamics. Ultimately, these
further investigations might help designing new treatment
strategies for aggressive breast cancer based on disrupting
Fig. 7 Induced ERK5 silencing
suppresses breast cancer lung
metastasis. Control (dox−) and
doxycycline-fed (dox+) mice
bearing mammary tumor grafts
were paired according to similar
tumor size. A, B Breast
metastasis was detected post
mortem by quantification of live
(DAPI−) breast cancer cells
(tdT+) in the lung. A
representative flow cytometry
analysis is shown in B. The
graphical analysis of the data
demonstrated that ERK5
knockdown significantly
reduced metastatic burden. Ratio
paired t test was applied for p
value calculation, p ≤ 0.01 (**).
Raw numbers utilized for the
graph are presented in the table.
C Breast metastasis to the spleen
and bone were detected by
bioluminescence imaging in one
control (dox−) animal of a pair
sacrificed at 4 weeks after dox
exposure.
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For constitutive ERK5 knockdown experiments in vitro,
shRNA lentiviral transduction particles were purchased
from Sigma-Aldrich to target the 3′UTR
(#TRCN0000197264) or the CDS (#TRCN0000010275) of
the erk5 transcript. shScr lentiviral particles (#SHC016V)
were utilized as controls. To generate doxycycline-
dependent inducible ERK5shRNA, oligonucleotides were
designed against the GACCCACCTTTCAGCCTTA
sequence at position 5639–5657 in the 3′UTR of the erk5
gene (Gene ID: 5598). Double-stranded oligonucleotides
were subcloned using AgeI and EcoRI in Tet-pLKO-puro-
IRES-Luc2=tdT, a lentiviral transfer plasmid created by
inserting a Luc2=tdT fragment (Addgene #32904) into the
Tet-pLKO-puro vector (Addgene #21915). Sequences for
shERK5i are available in Supplementary Table S1. To
construct doxycycline-dependent inducible expression sys-
tems, F-ERK5(WT) or D200A mutant cDNAs were sub-
cloned using PacI and NheI into the bicistronic lentiviral
expression vector pCHD-TRE3GS-MCS-EF1a-iRFP720 (a
gift from Stuart Cain, University of Manchester, in which
target cDNA expression is driven by the TRE3GS promoter
and iRFP720 expression is driven by the EF-1α core pro-
moter). Sequences for PCR amplification are available in
Supplementary Table S1.
Lentiviral infection of MDA-MB-231 cells
MDA-MB-231 cells were incubated for 24 h with viral
particles at 1 to 2 MOI in the presence of 8 µg/ml polybrene.
Infected cells with the pLKO recombinant plasmid were
subsequently selected by incubation with 3 µg/ml pur-
omycin until no live cells remained in the non-infected
group (at least 3 days). Resistant colonies were pooled and
expanded in puromycin-containing medium. Alternatively,
MDA-MB-231 cells transduced with doxycycline-inducible
F-ERK5(WT) or F-ERK5(D200A) delivering particles for
24 h were selected by FACS for iRFP720 fluorescence
2 days later.
Transwell invasion assay and measurement of cell
adhesion
For cell invasion, MDA-MB-231 cells were resuspended in
FBS-free medium and seeded at a low density of 10,000
cells per well in the upper Boyden chamber of 24-well
plates with 8-μm pore (Corning #353097) coated with
Matrigel. The lower chamber was filled with culture med-
ium without FBS. 16 h after seeding, the cells on the bottom
layer surface were stained with 0.05% crystal violet dye and
quantified under the microscope. Cell adhesion in Matrigel-
coated plates was monitored by IncuCyte® live cell analysis.
Four fields of view were set up for each well. The number
of cells in each field was counted in real time, every 10 min.
Adherent cells were distinguished from non-adherent cells
based on a larger cell surface area. Triplicate data were used
for statistical analysis.
Mammary tumor grafts
Eighteen adult female CD1 nude mice were injected in the
mammary fad pad (4th nipple orthotopic) with MDA-MB-
231 cells carrying the shERK5(UTR-2)-Luc=tdT construct
(2 × 106 cells in 50 μl PBS mixed with 50 μl Matrigel). After
small tumors were established, 9 mice received doxycycline
in their diet, while 9 control animals were fed with a stan-
dard doxycycline-free diet. Tumor size was determined by
caliper measurements of tumor length, width and depth and
expressed as volume in mm3 (0.52 × length × width ×
depth). Four experimental mice in each cohort exhibited
tumors that stopped growing few weeks after the intro-
duction of the dox+ or dox− diets. Therefore, 5 animals per
groups were utilized for statistical analysis to confirm the
effect and rule out artefacts associated with biological
variability. In parallel, tumor growth was analyzed by bio-
luminescence imaging. Mice received an intraperitoneal
injection of 100 μl of luciferin (30 mg/ml) and imaged using
a bioluminescent imaging system (PhotonImager Opitma,
Biospace Lab, France). Images from dox− and dox+ group
were captured under identical imaging conditions at iden-
tical times after luciferin injection.
Analysis of mammary tumor lung metastasis by flow
Cytometry
Metastasis was analyzed post mortem in the lung of mice
bearing large mammary tumor grafts (around
700~800 mm3). In brief, lungs were collected, minced in a
Petri dish on ice and sequentially digested in Hanks
balanced salt solution (HBSS) containing collagenase
(1.25 mg/ml) and hyaluronidase (125 μg/ml) for 30 min,
trypsin-EDTA for 3 min, and dispase (5 mg/ml) and DNase
(10 mg/ml) for 3 min. Neutralization with 1% FBS-
containing HBSS was conducted between each enzymatic
digestion, following centrifugation at 5000 rpm. The final
cell suspension was filtered through a 40 μm cell strainer.
Red blood cells were solubilized with red cell lysis buffer
(Pharm Lyse, BD Biosciences) and the resulting suspension
was filtered through a cell strainer to produce single-cell
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suspensions. Dissociated cells were washed twice in PBS
and incubated with DAPI (blue). For analysis, a typical
forward- and side-scatter gate was set to exclude dead cells
and aggregates; a total of 2 × 106 events in the gate were
collected using the BD Biosciences LSR Fortessa cyt-
ometer. tdTomato positive cells were quantified using
Flowjo software.
Kaplan–Meier analysis
Kaplan–Meier plots were generated through the Jetset best
probes (dataset number # ‘35617_at’ for ERK5 and
‘208820_at’ for FAK) to evaluate the prognostic sig-
nificance of ERK5 and FAK mRNA in distant metastasis-
free survival (http://www.kmplot.com). For Fig. 1, patient
specimens were divided into high and low expression
groups according to the median expression. The median
was computed before any subgroups were analyzed. Con-
sequently, the same threshold of ERK5 transcript level was
utilized in all panels. The grade subgroup information was
determined in the website database. For Figs. 2B, S4A and
S4C, patient data were analyzed using the best cutoff to
distinguish high and low expression groups. Patients
marked as ‘ER negative’, ‘PR negative’ and ‘HER2 nega-
tive’ were grouped as TNBC patients. Hazard ratios (HR)
with 95% confidence intervals and logrank P values were
calculated automatically by the website software.
Statistical analyses
Results were analyzed using the two-way ANOVA test to
compare time courses. For normally distributed data, an
unpaired two-tailed Student’s t test was performed. Statis-
tical significance was set at *p ≤ 0.05, **p ≤ 0.01, ***p ≤
0.001; ns indicates no statistical difference. For in vivo
analysis of metastatic burden, the number of breast cancer
cells extracted from the lung of paired tumor-bearing mice
was normalized as ratios (doxdoxþ, when dox+ is 0, calculate it
as 1) and compared using a ratio paired t test.
Additional materials and methods are listed in the Sup-
plementary information.
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